$0.90
+0.09 (+10.89%)
Open$0.83
Previous Close$0.81
Day High$0.92
Day Low$0.82
52W High$16.51
52W Low$6.89
Volume—
Avg Volume761.1K
Market Cap88.09M
P/E Ratio—
EPS$-1.39
SectorBiotechnology
Analyst Ratings
Hold
16 analysts
Price Target
+1,214.8% upside
Current
$0.90
$0.90
Target
$11.82
$11.82
$9.31
$11.82 avg
$19.97
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 12.75M | 11.28M | 11.12M |
| Net Income | 2.52M | 2.04M | 2.05M |
| Profit Margin | 19.8% | 18.1% | 18.5% |
| EBITDA | 3.36M | 2.88M | 2.97M |
| Free Cash Flow | 1.75M | 1.40M | 1.41M |
| Rev Growth | -0.1% | +22.8% | +18.0% |
| Debt/Equity | 0.25 | 0.20 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |